Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Virginia Coreil

Pediatrics Lafayette, LA Medical Doctor

NPI 1053319780 CMS profile 1019702

5000 Ambassador Caffery Pkwy Bldg 12, Lafayette, LA 70508

Open in the dashboard

General payments

$2,668

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Virginia Coreil of Lafayette, LA is reported in the CMS Open Payments database as having received $2,668 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $449 27
2024 General $581 26
2023 General $229 15
2022 General $387 29
2021 General $301 20
2020 General $190 12
2019 General $532 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Virginia Coreil
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Virginia Coreil were reported at $449. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Virginia Coreil Pediatrics median Middle half National median
2019 $532 $86 $31–$183 $163
2020 $190 $49 $22–$110 $114
2021 $301 $68 $27–$158 $132
2022 $387 $77 $30–$173 $149
2023 $229 $88 $33–$190 $160
2024 $581 $94 $34–$206 $164
2025 $449 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $606 33 payments
  2. Tris Pharma Inc $291 19 payments
  3. Ironshore Pharmaceuticals Inc. $225 13 payments
  4. GlaxoSmithKline, LLC. $218 16 payments
  5. Adlon Therapeutics L.P. $165 10 payments
  6. Corium, Inc. $157 12 payments
  7. Neos Therapeutics, LP $124 7 payments
  8. Sanofi Pasteur Inc. $123 8 payments
  9. Pfizer Inc. $115 6 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $85 5 payments
  11. Other $560 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,668 164 payments
Products named General payments · program years 2019–2025
  1. Qelbree Viloxazine Hydrochloride $384 15 payments
  2. QELBREE Psychology $222 18 payments
  3. BEXSERO $193 14 payments
  4. PEDIARIX $191 14 payments
  5. ADHANSIA XR $165 10 payments
  6. Dyanavel XR $161 11 payments
  7. Azstarys $157 12 payments
  8. VYVANSE $115 7 payments
  9. TRUMENBA $115 6 payments
  10. PREVNAR 20 $115 6 payments
  11. Other $1,888 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record